Cargando…

Nonremission and Recurrent Tumor‐Induced Osteomalacia: A Retrospective Study

Tumor‐induced osteomalacia (TIO) is a rare paraneoplastic syndrome. It is curable by excision of the causative tumor. However, a few cases may persist or relapse after tumor resection. We aimed to investigate the rate of these events and related factors. We retrospectively studied TIO patients treat...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xiang, Jiang, Yan, Huo, Li, Wu, Huanwen, Liu, Yong, Jin, Jin, Yu, Wei, Lv, Wei, Zhou, Lian, Xia, Yu, Wang, Ou, Li, Mei, Xing, Xiaoping, Chi, Yue, Jiajue, Ruizhi, Cui, Lijia, Meng, Xunwu, Xia, Weibo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7140180/
https://www.ncbi.nlm.nih.gov/pubmed/31643101
http://dx.doi.org/10.1002/jbmr.3903
_version_ 1783518936825856000
author Li, Xiang
Jiang, Yan
Huo, Li
Wu, Huanwen
Liu, Yong
Jin, Jin
Yu, Wei
Lv, Wei
Zhou, Lian
Xia, Yu
Wang, Ou
Li, Mei
Xing, Xiaoping
Chi, Yue
Jiajue, Ruizhi
Cui, Lijia
Meng, Xunwu
Xia, Weibo
author_facet Li, Xiang
Jiang, Yan
Huo, Li
Wu, Huanwen
Liu, Yong
Jin, Jin
Yu, Wei
Lv, Wei
Zhou, Lian
Xia, Yu
Wang, Ou
Li, Mei
Xing, Xiaoping
Chi, Yue
Jiajue, Ruizhi
Cui, Lijia
Meng, Xunwu
Xia, Weibo
author_sort Li, Xiang
collection PubMed
description Tumor‐induced osteomalacia (TIO) is a rare paraneoplastic syndrome. It is curable by excision of the causative tumor. However, a few cases may persist or relapse after tumor resection. We aimed to investigate the rate of these events and related factors. We retrospectively studied TIO patients treated with surgery in a tertiary hospital. TIO was established based on a pathologic examination or the reversion of hypophosphatemia. Refractory TIO patients consisted of those with nonremission or recurrent hypophosphatemia after surgery. A total of 230 patients were confirmed as having TIO. After primary surgery, 26 (11.3%) cases persisted, and 16 (7.0%) cases recurred. The overall refractory rate was 18.3%. The median time of recurrence was 33 months. Compared with patients in the recovery group, patients in the refractory group were more likely to be female (59.5% versus 41.0%, p = .029) and have a lower serum phosphate level (0.44 ± 0.13 versus 0.50 ± 0.11 mmol/L, p = .002). The refractory rate was lowest in head/neck tumors (7.5%) and highest in spine tumors (77.8%). Regarding the tissue involved of tumor location, the refractory rate was higher in tumors involving bone than tumors involving soft tissue (32.7% versus 7.0%, p < .001). The outcomes of malignant tumors were worse than those of benign tumors (p < .001): nonremission rate, 21.4% versus 9.7%; recurrence rate, 28.6% versus 6.5%. In the multivariate regression analysis, female sex, spine tumors, bone tissue‐involved tumors, malignancy, and low preoperation serum phosphorus levels were identified as risk factors for refractory outcomes. High preoperative fibroblast growth factor 23 (FGF23) levels were also associated with refractory after adjusting for involving tissue and tumor malignancy. In summary, we are the first to report the rate and clinical characteristics of refractory TIO in a large cohort. For patients with multiple risk factors, especially spine tumors, clinical practitioners should be aware of a poor surgical prognosis. © 2019 The Authors. Journal of Bone and Mineral Research published by American Society for Bone and Mineral Research.
format Online
Article
Text
id pubmed-7140180
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-71401802020-04-08 Nonremission and Recurrent Tumor‐Induced Osteomalacia: A Retrospective Study Li, Xiang Jiang, Yan Huo, Li Wu, Huanwen Liu, Yong Jin, Jin Yu, Wei Lv, Wei Zhou, Lian Xia, Yu Wang, Ou Li, Mei Xing, Xiaoping Chi, Yue Jiajue, Ruizhi Cui, Lijia Meng, Xunwu Xia, Weibo J Bone Miner Res Original Articles Tumor‐induced osteomalacia (TIO) is a rare paraneoplastic syndrome. It is curable by excision of the causative tumor. However, a few cases may persist or relapse after tumor resection. We aimed to investigate the rate of these events and related factors. We retrospectively studied TIO patients treated with surgery in a tertiary hospital. TIO was established based on a pathologic examination or the reversion of hypophosphatemia. Refractory TIO patients consisted of those with nonremission or recurrent hypophosphatemia after surgery. A total of 230 patients were confirmed as having TIO. After primary surgery, 26 (11.3%) cases persisted, and 16 (7.0%) cases recurred. The overall refractory rate was 18.3%. The median time of recurrence was 33 months. Compared with patients in the recovery group, patients in the refractory group were more likely to be female (59.5% versus 41.0%, p = .029) and have a lower serum phosphate level (0.44 ± 0.13 versus 0.50 ± 0.11 mmol/L, p = .002). The refractory rate was lowest in head/neck tumors (7.5%) and highest in spine tumors (77.8%). Regarding the tissue involved of tumor location, the refractory rate was higher in tumors involving bone than tumors involving soft tissue (32.7% versus 7.0%, p < .001). The outcomes of malignant tumors were worse than those of benign tumors (p < .001): nonremission rate, 21.4% versus 9.7%; recurrence rate, 28.6% versus 6.5%. In the multivariate regression analysis, female sex, spine tumors, bone tissue‐involved tumors, malignancy, and low preoperation serum phosphorus levels were identified as risk factors for refractory outcomes. High preoperative fibroblast growth factor 23 (FGF23) levels were also associated with refractory after adjusting for involving tissue and tumor malignancy. In summary, we are the first to report the rate and clinical characteristics of refractory TIO in a large cohort. For patients with multiple risk factors, especially spine tumors, clinical practitioners should be aware of a poor surgical prognosis. © 2019 The Authors. Journal of Bone and Mineral Research published by American Society for Bone and Mineral Research. John Wiley & Sons, Inc. 2019-11-15 2020-03 /pmc/articles/PMC7140180/ /pubmed/31643101 http://dx.doi.org/10.1002/jbmr.3903 Text en © 2019 The Authors. Journal of Bone and Mineral Research published by American Society for Bone and Mineral Research This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Li, Xiang
Jiang, Yan
Huo, Li
Wu, Huanwen
Liu, Yong
Jin, Jin
Yu, Wei
Lv, Wei
Zhou, Lian
Xia, Yu
Wang, Ou
Li, Mei
Xing, Xiaoping
Chi, Yue
Jiajue, Ruizhi
Cui, Lijia
Meng, Xunwu
Xia, Weibo
Nonremission and Recurrent Tumor‐Induced Osteomalacia: A Retrospective Study
title Nonremission and Recurrent Tumor‐Induced Osteomalacia: A Retrospective Study
title_full Nonremission and Recurrent Tumor‐Induced Osteomalacia: A Retrospective Study
title_fullStr Nonremission and Recurrent Tumor‐Induced Osteomalacia: A Retrospective Study
title_full_unstemmed Nonremission and Recurrent Tumor‐Induced Osteomalacia: A Retrospective Study
title_short Nonremission and Recurrent Tumor‐Induced Osteomalacia: A Retrospective Study
title_sort nonremission and recurrent tumor‐induced osteomalacia: a retrospective study
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7140180/
https://www.ncbi.nlm.nih.gov/pubmed/31643101
http://dx.doi.org/10.1002/jbmr.3903
work_keys_str_mv AT lixiang nonremissionandrecurrenttumorinducedosteomalaciaaretrospectivestudy
AT jiangyan nonremissionandrecurrenttumorinducedosteomalaciaaretrospectivestudy
AT huoli nonremissionandrecurrenttumorinducedosteomalaciaaretrospectivestudy
AT wuhuanwen nonremissionandrecurrenttumorinducedosteomalaciaaretrospectivestudy
AT liuyong nonremissionandrecurrenttumorinducedosteomalaciaaretrospectivestudy
AT jinjin nonremissionandrecurrenttumorinducedosteomalaciaaretrospectivestudy
AT yuwei nonremissionandrecurrenttumorinducedosteomalaciaaretrospectivestudy
AT lvwei nonremissionandrecurrenttumorinducedosteomalaciaaretrospectivestudy
AT zhoulian nonremissionandrecurrenttumorinducedosteomalaciaaretrospectivestudy
AT xiayu nonremissionandrecurrenttumorinducedosteomalaciaaretrospectivestudy
AT wangou nonremissionandrecurrenttumorinducedosteomalaciaaretrospectivestudy
AT limei nonremissionandrecurrenttumorinducedosteomalaciaaretrospectivestudy
AT xingxiaoping nonremissionandrecurrenttumorinducedosteomalaciaaretrospectivestudy
AT chiyue nonremissionandrecurrenttumorinducedosteomalaciaaretrospectivestudy
AT jiajueruizhi nonremissionandrecurrenttumorinducedosteomalaciaaretrospectivestudy
AT cuilijia nonremissionandrecurrenttumorinducedosteomalaciaaretrospectivestudy
AT mengxunwu nonremissionandrecurrenttumorinducedosteomalaciaaretrospectivestudy
AT xiaweibo nonremissionandrecurrenttumorinducedosteomalaciaaretrospectivestudy